Comparative Pharmacology
Head-to-head clinical analysis: LOCOID LIPOCREAM versus UTICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOCOID LIPOCREAM versus UTICORT.
LOCOID LIPOCREAM vs UTICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Locoid Lipocream contains hydrocortisone butyrate, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, reduces mast cell degranulation, and decreases vascular permeability.
Uticort (betamethasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Apply a thin layer to affected area twice daily. Maximum duration of continuous treatment: 4 weeks.
Topical: Apply a thin film to affected area twice daily. Maximum 50 g per week. For short-term use only (≤2 weeks).
None Documented
None Documented
Terminal elimination half-life: ~6-8 hours (hydrocortisone butyrate); clinical context: supports twice-daily dosing
Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 6-12 hours in hepatic impairment.
Renal: ~1.5% as unchanged hydrocortisone butyrate and metabolites; Biliary/fecal: ~85% as metabolites
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% via enterohepatic circulation.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid